Prolonging remission with rituximab maintenance therapyHAINSWORTH, John D.Seminars in oncology. 2004, Vol 31, pp 17-21, issn 0093-7754, 5 p., SUP2Article

Treatment for Patients With Unknown Primary Cancer and Favorable Prognostic FactorsHAINSWORTH, John D; FIZAZI, Karim.Seminars in oncology. 2009, Vol 36, Num 1, pp 44-51, issn 0093-7754, 8 p.Article

Cancers of Unknown Primary SiteGRECO, F. Anthony; HAINSWORTH, John D.Seminars in oncology. 2009, Vol 36, Num 1, issn 0093-7754, 82 p.Serial Issue

Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: A phase II trial of the minnie pearl cancer research networkHAINSWORTH, John D; CALVERT, Sharon; GRECO, F. Anthony et al.Cancer investigation. 2002, Vol 20, Num 7-8, pp 863-871, issn 0735-7907, 9 p.Article

Rituximab as first-line systemic therapy for patients with low-grade lymphomaHAINSWORTH, John D.Seminars in oncology. 2000, Vol 27, Num 6, pp 25-29, issn 0093-7754, SUP12Conference Paper

Oral chemotherapy: past, present and future directionsGRECO, F. Anthony; HAINSWORTH, John D.Drugs (Basel). 1999, Vol 58, issn 0012-6667, 147 p., SUP3Conference Proceedings

Prognostic Factors in Unknown Primary CancerCULINE, Stéphane.Seminars in oncology. 2009, Vol 36, Num 1, pp 60-64, issn 0093-7754, 5 p.Article

First-line and maintenance treatment with rituximab for patients with indolent non-Hodgkin's lymphomaHAINSWORTH, John D.Seminars in oncology. 2003, Vol 30, Num 1, pp 9-15, issn 0093-7754, 7 p., SUP2Article

Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma : Interim follow-up of a multicenter phase ii trialHAINSWORTH, John D.Seminars in oncology. 2002, Vol 29, Num 1, pp 25-29, issn 0093-7754, SUP2Article

Neuroendocrine Carcinoma of Unknown Primary SiteSPIGEL, David R; HAINSWORTH, John D; GRECO, F. Anthony et al.Seminars in oncology. 2009, Vol 36, Num 1, pp 52-59, issn 0093-7754, 8 p.Article

Pathologic Evaluation of Unknown Primary CancerOIEN, Karin A.Seminars in oncology. 2009, Vol 36, Num 1, pp 8-37, issn 0093-7754, 30 p.Article

Germ cell neoplasms and other malignancies of the mediastinumHAINSWORTH, John D; GRECO, F. Anthony.Cancer treatment and research. 2001, Vol 105, pp 303-325, issn 0927-3042Article

Oral etoposide in germ cell tumoursSAXMAN, S.Drugs (Basel). 1999, Vol 58, pp 31-34, issn 0012-6667, SUP3Conference Paper

Final Survival and Safety Results From a Multicenter, Open-label, Phase 3b Trial of Erlotinib in Patients With Advanced Nonsmall Cell Lung CancerSPIGEL, David R; MING LIN; O'NEILL, Vincent et al.Cancer. 2008, Vol 112, Num 12, pp 2749-2755, issn 0008-543X, 7 p.Article

Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non-small cell lung cancerHAINSWORTH, John D; BURRIS, Howard A; GRECO, F. Anthony et al.Seminars in oncology. 2001, Vol 28, Num 3, pp 21-25, issn 0093-7754, SUP9Conference Paper

Treatment for Patients With Unknown Primary Carcinoma and Unfavorable Prognostic FactorsGRECO, F. Anthony; PAVLIDIS, Nicholas.Seminars in oncology. 2009, Vol 36, Num 1, pp 65-74, issn 0093-7754, 10 p.Article

Recent developments in oral chemotherapy options for gastric carcinomaAJANI, J. A; TAKIUCHI, H.Drugs (Basel). 1999, Vol 58, pp 85-90, issn 0012-6667, SUP3Conference Paper

Oral chemotherapy in head and neck cancerBROCKSTEIN, B. E; VOKES, E. E.Drugs (Basel). 1999, Vol 58, pp 91-97, issn 0012-6667, SUP3Conference Paper

New oral chemotherapeutic agents for lung cancerBENGTSON, E. M; RIGAS, J. R.Drugs (Basel). 1999, Vol 58, pp 57-69, issn 0012-6667, SUP3Conference Paper

Molecular Profiling Diagnosis in Unknown Primary Cancer: Accuracy and Ability to Complement Standard PathologyGRECO, F. Anthony; LENNINGTON, Wayne J; SPIGEL, David R et al.Journal of the National Cancer Institute. 2013, Vol 105, Num 11, pp 782-790, issn 0027-8874, 9 p.Article

Molecular Classification of Unknown Primary CancerBENDER, Richard A; ERIANDER, Mark G.Seminars in oncology. 2009, Vol 36, Num 1, pp 38-43, issn 0093-7754, 6 p.Article

Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma : A minnie pearl cancer research network studyHAINSWORTH, John D; SPIGEL, David R; LITCHY, Sharlene et al.Journal of clinical oncology. 2006, Vol 24, Num 22, pp 3548-3554, issn 0732-183X, 7 p.Article

Oral etoposide in lymphomaGRECO, F. A.Drugs (Basel). 1999, Vol 58, pp 35-41, issn 0012-6667, SUP3Conference Paper

Oral cancer chemotherapy in paediatric patients: Obstacles and potential for development and utilisationBLEYER, W. A; DANIELSON, M. G.Drugs (Basel). 1999, Vol 58, pp 133-140, issn 0012-6667, SUP3Conference Paper

Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer : A review of The Sarah Cannon Cancer Center experienceHAINSWORTH, John D; BURRIS, Howard A; GRECO, F. Anthony et al.Seminars in oncology. 2001, Vol 28, Num 2, pp 43-47, issn 0093-7754, SUP4Conference Paper